NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Maria Soler Nunez appointed as Chief Quality Officer
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Subscribe To Our Newsletter & Stay Updated